Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia.
Why Direct-to-Patient Access Matters for Presbyopia Patients
Access and adherence remain persistent challenges in ophthalmology, where treatments are often underutilized due to a complex patient journey with high affordability barriers. Presbyopia, an ophthalmic condition that affects nearly 128 million Americans and approximately 2 billion people globally, has traditionally seen patients go untreated due to high out-of-pocket costs and limited therapy access (AOA, 2023). The opportunity to help meaningfully improve access to presbyopia therapy for millions of patients has never been greater.
Modernizing the Access Journey for YUVEZZI™
Tenpoint and PHIL have partnered to launch an innovative DTP program, delivering YUVEZZI™ directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support. This groundbreaking partnership reflects our shared commitment to improving how presbyopia patients receive therapy through reducing access barriers, lowering out-of-pocket costs, and supporting long-term treatment adherence for presbyopia patients.
“We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI™— a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what’s possible when patient access is a top priority.” – Deepak Thomas, CEO & Founder, PHIL
About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.1,2 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com.
